BRPI0514108A - polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos - Google Patents

polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos

Info

Publication number
BRPI0514108A
BRPI0514108A BRPI0514108-7A BRPI0514108A BRPI0514108A BR PI0514108 A BRPI0514108 A BR PI0514108A BR PI0514108 A BRPI0514108 A BR PI0514108A BR PI0514108 A BRPI0514108 A BR PI0514108A
Authority
BR
Brazil
Prior art keywords
polypeptide
polynucleotides
gag
polynucleotide
purifying
Prior art date
Application number
BRPI0514108-7A
Other languages
English (en)
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0514108A publication Critical patent/BRPI0514108A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

POLIPEPTìDEO, PROCESSO PARA PURIFICAR O MESMO, COMPOSIçãO, POLINUCLEOTìDEO OU POLINUCLEOTIDEOS Esta invenção diz respeito a novas fusões de polipeptídeos de HIV e polinucleotídeos de Gag, Pol e Nef, que são úteis nas composições e vacinas imunogênicas. A invenção diz respeito, em particular, a um polipeptídeo que compreende Nef ou um seu fragmento imunogênico, e Gag de pl7 e/ou Gag de p24 ou seus fragmentos imunogênicos, em que, quanto tanto Gag de p17 quanto de p24 se acham presentes, existe pelo menos um antígeno de HIV ou fragmento imunogênico entre eles. O polipeptídeo também pode compreender Pol ou RT ou um seu fragmento imunogênico.
BRPI0514108-7A 2004-08-05 2005-08-03 polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos BRPI0514108A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine
PCT/EP2005/008434 WO2006013106A2 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection

Publications (1)

Publication Number Publication Date
BRPI0514108A true BRPI0514108A (pt) 2008-05-27

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514108-7A BRPI0514108A (pt) 2004-08-05 2005-08-03 polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos

Country Status (31)

Country Link
US (2) US7612173B2 (pt)
EP (3) EP1773999B1 (pt)
JP (3) JP2008507987A (pt)
KR (1) KR101501495B1 (pt)
CN (2) CN101035897B (pt)
AR (2) AR050102A1 (pt)
AT (1) ATE443769T1 (pt)
AU (1) AU2005268856B2 (pt)
BR (1) BRPI0514108A (pt)
CA (1) CA2575898C (pt)
CY (1) CY1109667T1 (pt)
DE (1) DE602005016810D1 (pt)
DK (1) DK1773999T3 (pt)
ES (3) ES2334044T3 (pt)
GB (1) GB0417494D0 (pt)
HR (1) HRP20090678T1 (pt)
IL (2) IL180947A0 (pt)
MA (1) MA28983B1 (pt)
MX (1) MX2007001515A (pt)
MY (1) MY145614A (pt)
NO (1) NO20070988L (pt)
NZ (1) NZ552976A (pt)
PE (1) PE20060577A1 (pt)
PL (1) PL1773999T3 (pt)
PT (1) PT1773999E (pt)
RU (1) RU2441878C2 (pt)
SG (1) SG155206A1 (pt)
SI (1) SI1773999T1 (pt)
TW (1) TWI365191B (pt)
WO (1) WO2006013106A2 (pt)
ZA (1) ZA200700771B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
AU2006245920A1 (en) * 2005-05-12 2006-11-16 Glaxo Group Limited Vaccine composition
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
PL2048955T3 (pl) 2006-07-21 2013-11-29 California Inst Of Techn Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
EP2142212A2 (en) * 2007-03-26 2010-01-13 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
TW200911304A (en) 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
KR20100109555A (ko) * 2007-12-21 2010-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CN102625714B (zh) * 2008-07-16 2015-08-19 贝勒研究院 基于将最大化的gag和nef靶向树突细胞的hiv疫苗
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
SG177744A1 (en) 2009-07-24 2012-02-28 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
CA2794558A1 (en) 2010-03-26 2011-09-29 Patricia Bourguignon Hiv vaccine
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
SG188624A1 (en) * 2010-09-27 2013-04-30 Glaxosmithkline Biolog Sa Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
NZ700340A (en) 2012-03-30 2017-02-24 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
KR102922000B1 (ko) 2019-07-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas
EP4126028A1 (en) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions and methods for treating and preventing coronaviruses
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
WO2023056284A1 (en) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
EP0717752B1 (en) 1993-05-18 2004-11-24 Macfarlane Burnet Centre For Medical Research Limited Therapeutic compounds
KR100355470B1 (ko) 1993-11-17 2003-02-17 도이체 오엠 아르 쯔나이미텔 게엠바하 글루코사민이당류,그의제조방법,이를함유하는제약학적조성물,및그의용도
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
JP4637356B2 (ja) 1998-08-04 2011-02-23 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
CA2393861A1 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
PT1240186E (pt) * 1999-12-23 2010-03-25 Int Aids Vaccine Initiative Melhorias em respostas imunitárias ou relacionadas com respostas imunitárias ao hiv
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2003046124A2 (en) 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN100392085C (zh) * 2001-09-20 2008-06-04 葛兰素集团有限公司 疫苗
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
US20030190308A1 (en) 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
ATE420658T1 (de) * 2002-03-19 2009-01-15 Powderject Res Ltd Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
WO2005030964A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
CA2575898C (en) 2015-09-29
DK1773999T3 (da) 2010-01-18
ES2486669T3 (es) 2014-08-19
SG155206A1 (en) 2009-09-30
EP1773999B1 (en) 2009-09-23
JP2011234722A (ja) 2011-11-24
JP6007212B2 (ja) 2016-10-12
NZ552976A (en) 2010-01-29
EP2130921A2 (en) 2009-12-09
TW200621806A (en) 2006-07-01
KR20070041765A (ko) 2007-04-19
PE20060577A1 (es) 2006-08-07
MY145614A (en) 2012-03-15
GB0417494D0 (en) 2004-09-08
DE602005016810D1 (de) 2009-11-05
RU2441878C2 (ru) 2012-02-10
SI1773999T1 (sl) 2010-01-29
EP2130921A3 (en) 2010-03-03
IL180947A0 (en) 2007-07-04
ZA200700771B (en) 2009-04-29
IL207575A0 (en) 2011-07-31
PT1773999E (pt) 2009-12-16
EP2280073A3 (en) 2011-06-29
US20100184836A1 (en) 2010-07-22
NO20070988L (no) 2007-05-04
EP2280073A2 (en) 2011-02-02
ES2334044T3 (es) 2010-03-04
JP5629647B2 (ja) 2014-11-26
AR050102A1 (es) 2006-09-27
US7612173B2 (en) 2009-11-03
US20070243203A1 (en) 2007-10-18
MX2007001515A (es) 2007-09-07
PL1773999T3 (pl) 2010-02-26
MA28983B1 (fr) 2007-11-01
CN102633866B (zh) 2015-04-15
CN101035897B (zh) 2012-02-01
CN102633866A (zh) 2012-08-15
TWI365191B (en) 2012-06-01
AU2005268856B2 (en) 2012-05-24
KR101501495B1 (ko) 2015-03-11
EP1773999A2 (en) 2007-04-18
HRP20090678T1 (hr) 2010-01-31
EP2280073B1 (en) 2014-06-11
RU2007104088A (ru) 2008-09-10
HK1108168A1 (en) 2008-05-02
CY1109667T1 (el) 2014-08-13
WO2006013106A2 (en) 2006-02-09
ES2445453T3 (es) 2014-03-03
JP2014239687A (ja) 2014-12-25
EP2130921B1 (en) 2013-11-20
AU2005268856A1 (en) 2006-02-09
ATE443769T1 (de) 2009-10-15
JP2008507987A (ja) 2008-03-21
CN101035897A (zh) 2007-09-12
AR080216A2 (es) 2012-03-21
WO2006013106A3 (en) 2006-08-17
CA2575898A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
BRPI0514108A (pt) polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos
BR112022023591A2 (pt) Proteína spike (s) do coronavírus modificada e métodos de uso da mesma
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
EA201000829A1 (ru) Вакцина
BR0114036A (pt) Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
Moming et al. Mapping of B-cell epitopes on the N-terminal and C-terminal segment of nucleocapsid protein from Crimean-Congo hemorrhagic fever virus
BRPI0409655B8 (pt) compostos heterocíclicos de ligação ao receptor para quimiocina com maior eficiência
PE20061372A1 (es) Composicion farmaceutica que contiene un vector adenovirus
BR112022024063A2 (pt) Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina
Yu et al. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites
UA98969C2 (ru) АНТИКОАГУЛЯНТНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ ДЛЯ ЛЕЧЕНИЯ тромботических состояний И ПЛАЗМОЗАМЕЩАЮЩИЙ РАСТВОР ДЛЯ КОРРЕКЦИИ ГИПЕРКОАГУЛЯНТНЫХ НАРУШЕНИЙ ПРИ ГЕМОДИЛЮЦИИ
EA200600560A1 (ru) Ингибиторы проникновения вируса вич
Andrabi et al. Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
DE602005015256D1 (de) Hetero-oligomere hiv-hüllproteine
BR9715035A (pt) Processo para produção da proteìna hìbrida
UY31568A1 (es) Nueva vacuna contra el hiv-1
RU2010133961A (ru) Укороченная форма белка p17 вич
Kwallah Novel approaches in the detection of Yellow Fever Virus in febrile patients visiting selected health facilities in Western Kenya
Valadez-González et al. Transmembrane glycoprotein cross reactive hiv-1/hiv-2 epitope
TH104137A (th) วัคซีน
DE60239815D1 (de) Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.